Rockwell Medical (RMTI) Stock Higher Today After FDA Approves Iron Replacement Drug

NEW YORK (TheStreet) -- Shares of Rockwell Medical are up 5.46% to $11.40 after the FDA approved the company's drug Triferic, which is used for treating iron loss in chronic kidney disease patients on dialysis, Reuters reports. Triferic is a unique iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron losses that occur during their dialysis treatment ...



from Content Keyword RSS http://ift.tt/1uRIQrf

via IFTTT